Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. The company offers anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products… Read more
Jiangsu Aidea Pharmaceutical Co Ltd (688488) - Total Liabilities
Latest total liabilities as of September 2025: CN¥762.97 Million CNY
Based on the latest financial reports, Jiangsu Aidea Pharmaceutical Co Ltd (688488) has total liabilities worth CN¥762.97 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Aidea Pharmaceutical Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangsu Aidea Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jiangsu Aidea Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dakota Gold Corp.
NYSE MKT:DC
|
USA | $3.29 Million |
|
Scientex Bhd
KLSE:4731
|
Malaysia | RM3.30 Billion |
|
Peoples Fin
NASDAQ:PFIS
|
USA | $4.75 Billion |
|
Ral Yatirim Holding AS
IS:RALYH
|
Turkey | TL6.97 Billion |
|
Citycon Oyj
PINK:COYJF
|
USA | $2.21 Billion |
|
Guangzhou Hangxin Aviation Technology Co Ltd
SHE:300424
|
China | CN¥1.74 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Jiangsu Aidea Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Aidea Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total liabilities of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥802.48 Million | +29.22% |
| 2023-12-31 | CN¥621.03 Million | +36.12% |
| 2022-12-31 | CN¥456.23 Million | +265.52% |
| 2021-12-31 | CN¥124.82 Million | +43.52% |
| 2020-12-31 | CN¥86.97 Million | -61.30% |
| 2019-12-31 | CN¥224.74 Million | +20.68% |
| 2018-12-31 | CN¥186.24 Million | +28.31% |
| 2017-12-31 | CN¥145.14 Million | +1.39% |
| 2016-12-31 | CN¥143.16 Million | -- |